To determine the market growth and use of various insulin drug delivery system including traditional and developing

delivery system.

Developing drug delivery system Market study of insulin delivery system Analyze the world market for insulin delivery system Future trend

1944 Standard Syringe

1955 Oral Agents

1970 Insulin Pump

1986 Insulin Pen

2006 Insulin Inhalers

Self administration of insulin through subcutaneous route Made of barrel, plunger & needle
The global market for insulin syringes is estimated to $1.1 billion

Composed of insulin cartridge & a dial to measure the dose & used with disposable pen needles.
Insulin pen controls more than 50 percent of market share in insulin delivery devices market.

Made up of an insulin reservoir connected to a tube, ending in a cannula or catheter, which is inserted under the skin of your abdomen
Delivers slowly and continuously The global insulin pumps market was valued at $586.4million in 2009, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 9% from 2009 to 2016.

The insulin can be administered to the lungs by an aqueous mist inhaler or a dry powder inhaler

Exubera, the first FDA and EMA approved inhaled insulin product, won the Wall Street Journal's Biomedical Innovation of the year award in 2006

Islet Cell Transplantation Ingulin gene therapy

Insulin Pills

S.NO 1 2 3 4 5 6

Country/Region USA Canada Europe Asia Africa Middle east

Extrapolated incidence 861,533 95,372 1,474,002 10,063,645 1,290,255 1,055,809

Australia and Southern Pacific

70,138

346 million people worldwide have diabetes

The development of technologies in the last decade have brought to limelight the strategies that hold some promise in turning non injectable insulin delivery from theory to reality. The approaches that seem to hold potential must be consolidated and converted to a working protocol. Among the recent advances, inhaled insulin may offer the first practical, non-invasive alternative to insulin injections.

The ultimate goal for the treatment of diabetes remains the development of a fully automated glucose-controlled device.

http://homepages.cae.wisc.edu http://www.who.int http://jpronline.info http://www.wisegeek.com http://www.medicinenet.com http://www.fda.gov http://medind.nic.in http://mediligence.com http://www.slideshare.net http://www.medicaldevice-network.com http://mediligence.com